LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-20
Case ID: NM_001040108.2_c.4289_4293del_20261120_221614
Framework: ACMG/AMP 2015
Variant classification summary

NM_001040108.2:c.4289_4293del

MLH3  · NP_001035197.1:p.(Arg1430LeufsTer7)  · NM_001040108.2
GRCh37: chr14:75483853 AGAGAC>A  ·  GRCh38: chr14:75017150 AGAGAC>A
Gene: MLH3 Transcript: NM_001040108.2
Final call
VUS
PM2 moderate
All criteria require review: For research and educational purposes only.
Gene
MLH3
Transcript
NM_001040108.2
Protein
NP_001035197.1:p.(Arg1430LeufsTer7)
gnomAD AF
8.679705237210145e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Likely Oncogenic
Interpretation summary
Generated evidence synthesis
1
VUS: PM2 moderate is supported by the extremely low population frequency of 14/1,612,958 alleles in gnomAD v4.1, with zero homozygotes.
Final determination: Under the generic ACMG/AMP 2015 fallback, one moderate criterion alone does not meet any pathogenic, likely pathogenic, likely benign, or benign combination threshold, so the final call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 Not met Met at moderate strength: the terminal-exon frameshift escapes NMD and removes 18 of 1454 residues (1.24%), triggering the named last-exon/NMD-escape downgrade. (PVS1 changed from met (moderate) to not_met)
pvs1_gene_context pvs1_variant_assessment pvs1_generic_framework PMID:25741868
PS1 N/A Not applicable: PS1 requires a missense variant, and this is a frameshift variant.
generic_acmg_combination_rules
PS2 Not assessed Not assessed: no documented proband phenotype, family-history assessment, or confirmed maternity and paternity is available for this variant.
clinvar
PS3 Not assessed Not assessed: the only functional study used a different truncated MLH3 construct and did not test c.4289_4293del.
PMID:10615123
PS4 Not met Not met: no affected-case count or case-control OR is available, and reviewed literature provides no exact-variant enrichment evidence despite gnomAD frequencies of 1/251454 and 14/1612958.
gnomad_v2 gnomad_v4 PMID:34043773
PM1 N/A Not applicable: PM1 requires a missense variant, and this is a frameshift variant.
generic_acmg_combination_rules
PM2 Met Met at Moderate: gnomAD v4.1 observes 14/1,612,958 alleles (AF 8.68e-06), below the <=0.0001 extremely-low-frequency PM2 cutoff, with zero homozygotes.
gnomad_v4 gnomad_v2
PM3 Not assessed Not assessed: no documented parental testing, phase, affected-proband observation, or pathogenic allele is available for NM_001040108.2:c.4289_4293del.
PM4 N/A Not applicable: PM4 requires a protein-length change, and this is a frameshift variant.
pvs1_generic_framework generic_acmg_combination_rules
PM5 N/A Not applicable: PM5 requires a missense variant, and this is a frameshift variant.
generic_acmg_combination_rules
PM6 Not assessed Not assessed: no report documents an assumed de novo occurrence or provides the proband and parental information needed to evaluate it.
clinvar
PP1 Not assessed Not assessed: no affected relatives or informative meioses are reported to demonstrate co-segregation of the variant with disease.
clinvar
PP2 N/A Not applicable: PP2 requires a missense variant, and this is a frameshift variant.
generic_acmg_combination_rules
PP3 N/A Not applicable: the variant is a frameshift, outside PP3's missense or splice-region/intronic scope.
PP4 Not assessed Not assessed: the patient's phenotype and family history are unavailable, so disease-specific phenotype specificity cannot be judged.
PP5 Not met Not met: ClinVar has two laboratory VUS submissions and zero expert-panel submissions, with no exact-variant Pathogenic or Likely pathogenic classification.
clinvar PMID:34043773
BA1 Not met Not met: gnomAD v4.1 grpmax FAF is 6.88e-06, far below the 0.05 BA1 threshold, with the qualifying NFE population contributing 1,179,980 observed alleles.
gnomad_v4 gnomad_v2
BS1 Not met Not met: gnomAD v4.1 grpmax FAF is 6.88e-06 (0.000688%), far below the generic BS1 threshold of 0.01 (1%).
gnomad_v4 PMID:25741868
BS2 Not met Not met: gnomAD v4.1 reports zero homozygotes for the variant, and no documented healthy-adult observation establishes BS2 for a dominant, recessive, or X-linked disorder.
gnomad_v4 gnomad_v2
BS3 Not assessed Not assessed: no assay tested c.4289_4293del and demonstrated no damaging effect on MLH3 protein function or splicing.
PMID:10615123
BS4 Not assessed Not assessed: no affected relatives are reported whose genotypes demonstrate that the variant fails to segregate with disease.
clinvar
BP1 N/A Not applicable: BP1 requires a missense variant, and this is a frameshift variant.
generic_acmg_combination_rules
BP2 Not assessed Not assessed: no documented cis or trans phase result with a pathogenic variant is available for NM_001040108.2:c.4289_4293del.
BP3 N/A Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a frameshift variant.
pvs1_generic_framework generic_acmg_combination_rules
BP4 N/A Not applicable: the variant is a frameshift, for which a no-impact splice prediction cannot support BP4.
BP5 Not assessed Not assessed: no case-level alternate molecular basis or alternate pathogenic diagnosis is documented for this exact variant.
BP6 Not met Not met: ClinVar shows two laboratory VUS submissions and zero expert-panel submissions, with no exact-variant Benign or Likely benign expert-panel classification.
clinvar
BP7 N/A Not applicable: BP7 requires a synonymous variant, and this is a frameshift variant.
generic_acmg_combination_rules
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.